About Contact Us Careers

Hemorrhoid Drugs Market Size & Share, by Drug Class (Topical Agents, Oral Medications); Distribution Channel; Route of Administration - SWOT Analysis, Competitive Strategic Insights, Regional Trends 2025-2037

  • Report ID: 3057
  • Published Date: Jun 20, 2025
  • Report Format: PDF, PPT

Hemorrhoid Drugs Market Outlook:

Hemorrhoid Drugs Market size was valued at USD 2.5 Billion in 2024 and is expected to cross USD 4.5 Billion by the end of 2037, registering more than 4.7% CAGR during the forecast period i.e., between 2025-2037. In 2025, the industry size of hemorrhoidal drugs is assessed at USD 2.7 billion.

The global hemorrhoidal drugs market is steadily increasing, with the increase in the patient pool estimated to be over 10.9 million people in the U.S. affected annually. Based on the data from the National Institute of Diabetes and Digestive and Kidney Diseases, approximately 1 in every 25 people experience the prevalence rates of hemorrhoids in America. Mostly, people aged over 45 are affected annually, with conditions including corticosteroids, vasoconstrictors, and analgesics. The supply chain of hemorrhoid drugs includes active pharmaceutical ingredients manufactured in China and India. Nearly 60.7% of the APIs for generic drugs are for the U.S. market. Medical devices, such as Hemorrhoid banding tools, a medical device  generally manufactured in regulated facilities with imported components from Europe and East Asia .

The pharmaceutical preparation's producer price index, based on the U.S. Bureau of Labor Statistics, depicts moderate growth in the hemorrhoidal drugs market. In Q1 2025, the PPI for pharmaceutical products increased by 2.2% YoY, affecting the input and logistics costs. The consumer price index for medical care commodities, including hemorrhoid drugs, increased 2% in 2024, showcasing a stable pricing on the consumer side despite upstream cost pressures. R&D expenditures for rectal and anorectal therapies remain focused within both NIH-funded public health initiatives and university-led clinical trials.

Hemorrhoid Drugs Market Size
Discover Market Trends & Growth Opportunities: Request Free Sample PDF

Growth Drivers 

  • Government spending through Medicare and Medicaid: The amount that the U.S. government spends on prescription drugs for painkillers, corticosteroids, and hemorrhoids are accurately tracked under Medicare Part D. Medicare Part D expenditure on gastrointestinal and rectal drugs was USD 2.9 billion in 2023 with the hemorrhoids representing a significant portion of the total because of aging populations based on Medicare.gov Drug expenditure Dashboard. In addition, Medicare outlays for outpatient GI services, including hemorrhoid management, totaled over USD 3.5 billion, reflecting a significant portion of the broader healthcare cost.

  • Increasing disease prevalence and aging population: The hemorrhoid drugs market is expanding with a large patient pool, especially in areas of North America and Europe. According to the German Federal Statistical Office and public health registries, the prevalence of symptomatic hemorrhoids in adults reached 6.9 million in 2025, especially among adults in Germany, showcasing nearly 13% growth in symptomatic hemorrhoids since 2018. Furthermore, in the U.S., nearly 11 million people have hemorrhoidal symptoms and seek annual medical attention. The correlation with aging, especially in those aged 45 and above, amplifies demand for prescription and OTC drugs.

Challenges

  • Government-imposed price caps: Various challenges arise with respect to the pricing of the drugs. Europe countries enforce price controls via national insurance systems. The AMNOG process in Germany demands limiting premium pricing negotiations, a mandatory price for new drugs. This minimizes the manufacturer's profitability and delays to time to market. However, in 2023, a global supplier partnered with Germany’s GKV-Spitzenverband and implemented an outcome-based pricing model, improving access by 10.1% while complying with price caps. Such collaborations are becoming necessary to navigate tight payer frameworks in Europe.

Hemorrhoid Drugs Market Size and Forecast:

Report Attribute Details

Base Year

2024

Forecast Year

2025-2037

CAGR

4.7%

Base Year Market Size (2024)

USD 2.5 billion

Forecast Year Market Size (2037)

USD 4.5 billion

Regional Scope

  • North America (U.S., and Canada) 
  • Asia Pacific (Japan, China, India, Indonesia, Malaysia, Australia, South Korea, Rest of Asia Pacific) 
  • Europe (UK, Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe) 
  • Latin America (Mexico, Argentina, Brazil, Rest of Latin America) 
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Access Detailed Forecasts & Data-Driven Insights: Request Free Sample PDF

Hemorrhoid Drugs Market Segmentation:

Distribution Channel Segment Analysis

In terms of distribution channels, retail pharmacies are the key players, leading the market share of 53% globally. Retail segments are crucial as it can reach the consumer conveniently and instantly. Pharmacies provide both prescription and OTC hemorrhoid drugs, supported by streamlined supply chains and regulatory approvals. Many government health programs in developed nations like the U.S. and Europe endorse pharmacy-based dispensing and improving its accessibility. According to the report by WHO, retail pharmacies in urban places play a crucial role in chronic disease management, including anorectal disorders.

Drug Class Segment Analysis

In the drug class segment, the topical drugs lead the market of hemorrhoid drugs market with a share of 47.0% globally. Hydrocortisone and lidocaine are some of the drug class that dominates the market due to their rapid symptomatic relief, reduced systemic side effects, and widespread OTC availability. According to the report of the U.S. National Library of Medicine, for Grade I–II hemorrhoids, topical treatments are the first line of defense, covering over 57% of treatment protocols in outpatient settings. Their low cost and inclusion in major insurance reimbursement plans have further expanded access.

Our in-depth analysis of the global hemorrhoid drugs market includes the following segments:  

Segment

Subsegment

Drug Class
  • Topical Agents
  • Oral Medications
  • Injectable Drugs

Route of Administration
  • Topical
  • Oral
  • Injectable
  • Rectal

Distribution Channel
  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies
  • Direct Sales
Vishnu Nair
Vishnu Nair
Head - Global Business Development

Customize this report to your requirements — connect with our consultant for personalized insights and options.

Hemorrhoid Drugs Market - Regional Analysis

North America Market Insights

The global hemorrhoid drugs market share is expected to be 32.5% in 2037. The hemorrhoid drugs market in North America is witnessing steady growth, primarily driven by an increase in disease prevalence, supportive government policies, and expanding healthcare funding. The U.S. has allocated nearly 9.5% of its healthcare budget, which is around USD 5.5 billion, for treating hemorrhoid conditions, reflecting a notable increase from previous years. Medicaid expanded its health insurance coverage up to USD 1.5 billion to hemorrhoid drug reimbursements, as the patient rate is growing steadily by 11% in 2024.

The hemorrhoid drugs market is set to rise in the U.S. with a rising prevalence of anorectal disorders, mostly seen in aging people and their lifestyle factors. The funding provided by the federal government has increased, with the CDC reporting 9.7% healthcare budget allocation to the treatments, which is approximately. USD 5.7 billion in 2023. Medicaid has expanded its coverage by reimbursing USD 1.6 billion, with a 10.7% increase in the reporting on patient coverage. This also enhances the patient's access to innovative therapies. Medicare’s spending on hemorrhoid drugs has risen by 15.6% from 2020 to 2024, reaching USD 800.7 million, reflecting the policy efforts to support and provide quality patient care. The U.S. market also benefits from advancements in OTC formulations, coupled with digital health integration.

Europe Market Insights

The hemorrhoid drugs market in Europe is projected to show steady growth till 2037 with the increase in the aging population, rise in healthcare expenditure, and rising prevalence of hemorrhoidal disease. A significant budget was allocated in 2023 by the region’s countries for their healthcare budgets to hemorrhoid treatments, making the market grow in demand. The EU has prioritized access via funding and innovation to hemorrhoid therapies, with funding exceeding €2.4 billion and supporting R&D related to the pharmaceutical sectors. The key drivers are government-related healthcare programs, patient awareness, and reimbursement policies.

The hemorrhoid drugs market in Germany has reached €4.6 billion in 2024, with a 12.7% increase since 2021. The investments in pharmaceutical innovation and reimbursement policies are supported by the Federal Ministry of Health to meet the market demand. Germany is the largest market in Europe, as it has an extensive healthcare infrastructure and an aging population. The aging population in the nation contributes to the rise in disease prevalence and increases the need for effective treatments. Some innovative formulations enhance the appeal, for instance, minimally invasive drug delivery systems and natural extract-based formulations market the market. In 2023, Germany saw a 10.4% increase in hemorrhoid drug demand, supported by a €300.1 million government research grant.

Hemorrhoid Drugs Market Share
Get Strategic Analysis by Region Now: Request Free Sample PDF

Key Hemorrhoid Drugs Market Players:

    Currently, a majority control over the revenue generation in the hemorrhoid drugs market is controlled by key pioneers, including NeoPharm, Pfizer, Servier, Astellas Pharma, and others. Additionally, the strategic PPPs and new launches are expanding the reach of this sector worldwide, even across underserved regions. The efforts to make associated products more affordable through cost-optimized manufacturing and resource localization are also propelling growth in this merchandise and attracting other developers related to mental health to invest in this category. Moreover, the competency among leading innovators is creating diverse opportunities across the value chain. 

    • NeoPharm
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Pfizer
    • Servier
    • Astellas Pharma
    • Alfa Wassermann
    • T.N. Dickinson’s
    • Johnson & Johnson
    • Microlabs
    • Roche
    • Sun Pharmaceutical
    • Generic (Multiple Firms)
    • Teva Pharmaceuticals
    • Intas Pharmaceuticals
    • Reckitt Benckiser Group plc
    • Sanofi S.A.
    • Bayer AG

Recent Developments

  • In February 2024, Pfizer expanded its hemorrhoidal care portfolio with the U.S. launch of an improved Hydrocortisone Acetate Suppository formulation featuring enhanced mucosal absorption.
  • In April 2025, Servier began exclusive distribution of Daflon 1000mg in South Korea and Malaysia. Backed by randomized clinical trials showing over 70% symptom improvement in Grade II hemorrhoids.
  • Report ID: 3057
  • Published Date: Jun 20, 2025
  • Report Format: PDF, PPT
  • Get detailed insights on specific segments/region
  • Inquire about report customization for your industry
  • Learn about our special pricing for startups
  • Request a demo of the report’s key findings
  • Understand the report’s forecasting methodology
  • Inquire about post-purchase support and updates
  • Ask About Company-Level Intelligence Additions

Have specific data needs or budget constraints?

customer-service Inquiry Before Buying

Frequently Asked Questions (FAQ)

In 2025, the industry size of hemorrhoidal drugs is assessed at USD 2.7 billion.

Hemorrhoid Drugs Market size was valued at USD 2.5 Billion in 2024 and is expected to cross USD 4.5 Billion by the end of 2037, registering more than 4.7% CAGR during the forecast period i.e., between 2025-2037.

The global hemorrhoid drugs market share is expected to be 32.5% in 2037.

NeoPharm, Pfizer, Servier, Astellas Pharma, Alfa Wassermann, T.N. Dickinson’s, Johnson & Johnson, Microlabs, Roche, Sun Pharmaceutical, Generic (Multiple Firms), Teva Pharmaceuticals, Intas Pharmaceuticals, Reckitt Benckiser Group plc, Sanofi S.A., Bayer AG.

Hemorrhoid Drugs Market Report Scope

GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

Connect with our Expert

Radhika Pawar
Radhika Pawar
Senior Research Analyst
Get a Free Sample

See how top U.S. companies are managing market uncertainty — get your free sample with trends, challenges, macroeconomic factors, charts, forecasts, and more.

Inquiry Before Buying Request Free Sample PDF

Copyright @ 2025 Research Nester. All Rights Reserved.

footer-bottom-logos